Status:
COMPLETED
Portal Pressure Effects of Phlebotomy Combined to Vasopressin Use in Cirrhotic Patients Undergoing Liver Transplantation
Lead Sponsor:
Centre hospitalier de l'Université de Montréal (CHUM)
Conditions:
Liver Transplantation
Portal Hypertension
Eligibility:
All Genders
18+ years
Brief Summary
Liver transplantation is the standard treatment for chronic advanced liver disease, whether or not associated with a primary liver tumor. The intraoperative bleeding and the need for blood transfusion...
Detailed Description
METHODS Objectives The primary objective will be to measure the hemodynamic effects of vasopressin on portal pressure in cirrhotic patients who have had a hypovolemic phlebotomy during a liver trans...
Eligibility Criteria
Inclusion
- Cirrhotic patients undergoing a liver transplantation
- 18 years and older
- Planned use of vasopressin during the surgery
Exclusion
- Fulminant or sub-fulminant hepatitis without underlying chronic liver disease
- Anesthetic plan does not include the use of vasopressin (contraindication or not relevant according to the anesthesiologist)
Key Trial Info
Start Date :
August 24 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 6 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04472312
Start Date
August 24 2020
End Date
July 6 2022
Last Update
July 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec, Canada, H2X 3E4